COMPANIES looking to invest in
clinical trials in Australia may be
reconsidering their options, after a
report found that the nation is the
second least competitive as a
market for clinical trial investment.
The 2012 KPMG Competitive
Alternatives report compared
business costs and other
competitiveness factors in more
than 110 cities in 14 countries, and
found that Australia is the second
most expensive country for
investing in clinical trials, behind
Japan, and that Sydney ranks 111th
out of 113 in the list of most
expensive cities, only topped by
Tokyo and Osaka.
Sydney was ...
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 21 May 12
Established in 2007, Pharmacy Daily is Australia's leading pharmacy industry publication, and is sent as a free subscription to people across the industry as a PDF newsletter every weekday.
To sign up for a free subscription, click on the button at right.
